We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · November 18, 2020

Changes in Respiratory Symptoms During 48-Week Treatment With Inhaled Liposomal Ciprofloxacin in Bronchiectasis

The European Respiratory Journal


Additional Info

Disclosure statements are available on the authors' profiles:

The European Respiratory Journal
Changes in Respiratory Symptoms During 48-Week Treatment With ARD-3150 (Inhaled Liposomal Ciprofloxacin) in Bronchiectasis: Results From the ORBIT-3 and -4 Studies
Eur. Respir. J. 2020 Oct 22;56(4)2000110, JD Chalmers, D Cipolla, B Thompson, AM Davis, A O'Donnell, G Tino, I Gonda, C Haworth, J Froehlich

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading